Paris France, June 21, 2017 - Terrass Hotel
This year the annual Oncology Drug Discovery Paris symposium focuses on the efficient translation of anticancer agents from bench to bedside.
This highly dynamic field has already seen tremendous change with the acceptance of key translational tools, such as patient-derived xenografts (PDX), and now needs further evolution to continue the advancement of immunotherapeutics.
The symposium will bring together Oncology R&D and Preclinical teams from industry, academia, and medical research to facilitate cross discipline discussions on current techniques, and how to move forward with future approaches.
Discussion Topics Include:
- How key translational oncology tools such as PDX models can be used to predict therapeutic response
- The evolution of immuno-oncology models, and current best practices for immunotherapuetic assessment
- How to expedite the development of novel targeted and immuno-oncology agents
For more information and registration visit the website: https://www.crownbio.com/paris17